10 Best Japanese Stocks To Own Right Now

After a few days of no real news earlier in the week, the markets seem to be using up all their stored energy. With the Dow Jones Industrial Average (DJINDICES: ^DJI  ) losing 80 points yesterday after spiking in earlier trading, the downward trend continues today. Down 49 points just after 11 a.m. EDT, the index is suffering from more speculation and discouraging international activity.

Outside the U.S.
The Asian markets fell overnight, with the Japanese Nikkei dropping 7.3% by the time the markets closed. With weak manufacturing data from China and increased bond yields in Japan, the pressure on the markets was too great. European markets followed suit, though losses were not as severe. Both the unexpected contraction in China and the eurozone are unsettling to U.S. investors.

10 Best Japanese Stocks To Own Right Now: Sarepta Therapeutics Inc (SRPT.W)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treat ment of individuals with DMD who have an error in the gene ! c! oding for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arra ngement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola viru! s in! fec! tion i! s AVI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 ! and are !! exploring! funding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

10 Best Japanese Stocks To Own Right Now: CABLE & WIRELESS COMMUNICATIONS ORD USD0.05(CWC.L)

Cable & Wireless Communications Plc, together with its subsidiaries, operates as a telecommunications company. The company provides mobile, broadband, and domestic/international fixed line services to consumers, businesses, and governments. It also offers mobile data services; entertainment services, such as pay TV services; data centers and hosting services; carrier, enterprise, and social telecoms services; managed services for corporate and Government clients; and financing services, as well as sells equipment, including handsets. The company provides services to approximately 10.7 million mobile, 630,000 broadband, and 1.6 million fixed line customers. It has operations in the Caribbean, Panama, Macau, Europe, the Middle East, Africa, and the Indian and Atlantic Oceans. The company was formerly known as Cable and Wireless plc and changed its name to Cable & Wireless Communications Plc in March 2010. Cable & Wireless Communications Plc was founded in 1929 and is headqua rtered in London, United Kingdom.

Top 10 Mid Cap Companies To Watch In Right Now: Brigadier Gold Limited (BRG.V)

Brigadier Gold Limited, an exploration stage company, engages in the acquisition, exploration, and development on mining properties in Canada and Argentina. It primarily explores for gold, copper, and silver, as well as other precious metals. The company�s principal property includes the Incamayo project consisting of 3,495 hectares located at the southeastern end of the Olacapata-El Toro Lineament in north western Argentina. It also holds interests in various mining claims in the Larder Lake mining division of northern Ontario, Canada; and various properties in Mozambique. Brigadier Gold Limited is headquartered in Toronto, Canada.

10 Best Japanese Stocks To Own Right Now: Oxygen Biotherapeutics Inc.(OXBT)

Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body in the United States. The company primarily offers Oxycyte, a perfluorcarbon (PFC) based oil in water emulsion that carries oxygen and is been formulated for intravenous delivery for the treatment of traumatic brain injury, spinal cord injury, and decompression sickness; and other PFC-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. It also provides Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. It markets its Dermacyte line of products through buydermacyte.com; and to dermatologists and medical spas with a combination of in-house sales, independent sales agents, and distributors. The company was formerly known as Synthetic Blood International, Inc. and changed its n ame to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics, Inc. was founded in 1967 and is based in Morrisville, North Carolina.

10 Best Japanese Stocks To Own Right Now: Endologix Inc(ELGX)

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of aortic disorders. It offers the ELG System, a stent graft and delivery system for the treatment of abdominal aortic aneurysms through minimally-invasive endovascular repair. The company also provides aortic extensions and limb extensions, which attach to the main body of ELG Device, enabling physicians to customize it to fit the patient?s anatomy. In addition, it offers accessories, such as guidewires, snares, and catheter introducer sheaths that facilitate the optimal delivery of its ELG Device. Endologix, Inc. sells its products through direct sales force and independent distributors in the United States, Europe, Asia, South America, and Mexico. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

10 Best Japanese Stocks To Own Right Now: Industrial Services of America Inc.(IDSA)

Industrial Services of America, Inc. engages in recycling stainless steel, ferrous, and non-ferrous scrap, as well as provides waste services. The company operates in two segments, Recycling and Waste Services. The Recycling segment collects, purchases, processes, and sells stainless steel, and ferrous and non-ferrous scrap metal to steel mini-mills, integrated steel makers, foundries, and refineries. It purchases ferrous and non-ferrous scrap metals from industrial and commercial generators of steel, iron, aluminum, copper, stainless steel, and other metals, as well as from scrap dealers and retail customers who deliver these materials directly to the company?s facilities. This segment also processes scrap metal through its sorting, shearing, shredding, cutting, and baling operations. In addition, it purchases, processes, and sells stainless steel, nickel-based, and high-temperature alloys. Further, this segment?s scrap recycling operations consist of collecting, sortin g, and processing various grades of copper, aluminum, and brass. The Waste Services segment provides waste management services, including contract negotiations with service providers, centralized billing, invoice auditing, and centralized dispatching. It also rents, leases, sells, and services waste handling and recycling equipment. This segment represents contracts with retail, commercial, and industrial businesses to handle their waste disposal needs, primarily by subcontracting with commercial waste hauling and disposal companies. The company offers its services primarily in the United States and Canada. Industrial Services of America, Inc. was founded in 1953 and is headquartered in Louisville, Kentucky.

10 Best Japanese Stocks To Own Right Now: Ivanhoe Energy Inc Com Npv(IE.TO)

Ivanhoe Energy Inc., together with its subsidiaries, engages in the development and production of oil and gas properties. The company holds interests in the Tamarack property, which is a 6,880 acre block located to the northeast of Fort McMurray, Alberta, Canada; the Zitong block that covers an area of approximately 248,000 gross acres and is located in the Sichuan basin, China; the Dagang field, which covers an area of 10,255 gross acres and is located in Hebei province, China; the Nyalga Block XVI that covers an area of approximately 3.1 million gross acres and is located in the Khenti and Tov provinces, Mongolia; and the Pungarayacu heavy oil field in Block 20 that covers an area of 426 square miles and is located to the southeast of Quito, Ecuador. As of December 31, 2011, it had 49 gross producing oil wells; and proved reserves of 1,729 thousand barrels. The company was formerly known as Black Sea Energy Limited and changed its name to Ivanhoe Energy Inc. in June 1999 . Ivanhoe Energy was founded in 1995 and is headquartered in Calgary, Canada.

10 Best Japanese Stocks To Own Right Now: Convergent Minerals Ltd(CVG.AX)

Convergent Minerals Ltd engages in the exploration and evaluation of mineral resources in Australia. It primarily explores for gold and nickel. The company holds 100% interest in the Bounty Gold Project comprising a tenement package of 42.06 square kilometers located southeast of Southern Cross, Western Australia. Convergent Minerals Ltd is based in West Perth, Australia.

10 Best Japanese Stocks To Own Right Now: Aurion Resources Ltd (AU.V)

Aurion Resources Ltd. engages in the evaluation, acquisition, and exploration of mineral properties in Canada, Mexico, and the United States. It holds interests in the Lavington gold and silver project located in British Columbia; Logan Pass and Bull projects located in Nevada; and La Bandera project located in Mexico. The company was incorporated in 2006 and is based in St. John's, Canada.

10 Best Japanese Stocks To Own Right Now: Digital Dispatch (DD.TO)

DDS Wireless International Inc. provides wireless mobile data solutions for vehicle fleet applications primarily in the United States, Canada, Europe, and internationally. The company engages in the design, development, and deployment of turnkey solutions, including application software, mobile devices, infrastructure products, professional services, and maintenance. It operates in four business units: Taxi, Transit, eFleet, and Digital Wireless. The Taxi business unit provides computerized dispatching and turnkey wireless fleet management solutions for taxi fleets; and TaxiBook, an Internet-based fleet management and dispatch solution. It also offers mobile commerce and Web-based interactive multimedia information, entertainment, and advertising solutions for taxis through a passenger information monitor. The Transit business unit provides mobile devices and wireless data infrastructure; scheduling, dispatching, and client management software; and service-based managed sc heduling and dispatching solutions for the transit market. The eFleet business unit offers software, hardware, and data networks that are accessible via Web browser to provide dispatching and management functionality for fleets of commercial vehicles. It integrates computer aided wireless dispatch, GPS fleet tracking, GPS navigation, two-way text messaging, and point-of-sale payment processing into a single hosted system. This business unit�s primary markets are work trucks, waste management trucks, and limousines. The Digital Wireless business unit provides in-vehicle wireless data computers, communications infrastructure products, and related in-vehicle peripheral devices. It markets its products as an OEM directly to customers and third-party solution providers. The company was formerly known as Digital Dispatch Systems Inc. and changed its name to DDS Wireless International Inc. in March 2008. The company was founded in 1978 and is headquartered in Richmond, Canada.